Urine and plasma specimens fortified with 82 drugs and metabolites were prepared and analyzed by liquid chromatography quadrupole time-of-flight mass spectrometry (QTOF) instrumentation from three different vendors using the instrument manufacturers' methods and workflows for drug screening. No prior knowledge about the compounds included or their concentrations were provided. Samples were prepared and sent for analysis on a TripleTOF â 5600 system, a 6530 QTOF and a Xevo â G2-S QTof. All three platforms performed well with >90% of compounds detected in one set of spiked plasma samples, and 79-88% for a second set of spiked plasma and two sets of spiked urine samples.
Introduction
General unknown or comprehensive drug screening utilized to detect commonly used prescription, over the counter and illicit drugs has traditionally been performed by gas chromatographymass spectrometry (GC -MS). This is considered the gold standard when used in the full-scan electron ionization mode utilized to provide documentation of drug exposure. Some of the benefits of using GC -MS for screening include: it affords high separation power and specificity, highly reproducible mass spectral data and the ability to detect hundreds to thousands of compounds in the mass spectral library (1) . The limitations of using GC -MS for drug screening are that compounds must have sufficient volatility and be thermally stable under high temperatures, there may be limitations in low end sensitivity for limit of detection (ng/mL versus mg/mL concentrations for various drugs), and sample preparation may be more extensive, especially if it involves derivatization or hydrolysis to improve the detection of some compounds (2) . Consequently, drug screening by liquid chromatography mass spectrometry (3 -7) and high-resolution accurate mass spectrometry has increased in recent years in order to detect drugs that are non-volatile, thermally labile and polar and to achieve lower analytical limits of detection. Liquid chromatography time-of-flight mass spectrometry (TOF) or quadrupole time-of-flight mass spectrometry (QTOF) has been used to detect drugs from multiple drug classes in blood, urine, meconium, hair and umbilical cord tissue (8 -16) . QTOF enables the acquisition of fragmentation information using a collision cell. In principle, QTOF offers increased specificity over TOF if MS-MS information can be acquired for all compounds during the analysis. Therefore, this platform provides an elegant solution for sensitive, specific identification of compounds in a comprehensive drug panel. This MS-MS information, however, may not be obtained for all compounds if the sample matrix is complex or if the acquisition time in not sufficient.
To determine the feasibility of developing a comprehensive drug screen using QTOF, nine plasma and nine urine samples containing 82 drugs and metabolites were prepared and analyzed by three different QTOF platforms. Of note, we were unable to obtain 'real' patient specimens that were positive for the number of compounds which were evaluated in this study, therefore, we used fortified samples. Fortified specimens were analyzed using a 1290 Infinity LC and autosampler (Agilent Technologies, Santa Clara, CA) and TripleTOF 5600 system (AB Sciex, Redwood City, CA, USA), an Agilent 1290 Infinity LC coupled to a 6530 QTOF (Agilent Technologies, Santa Clara, CA, USA) and an ACQUITY UPLC w and G2-S QTof (Waters Corporation, Milford, MA, USA). Samples were analyzed at the vendor sites and instrument performance, data analysis and reporting was evaluated at AB SCIEX in Foster City, CA, USA, the Agilent Center for Excellence in Santa Clara, CA, USA, and Waters Corporation in Beverly, MA. Samples were sent to each vendor with information about specimen type and the sample preparation method. No information was provided on the identity or concentration of drugs and metabolites that were spiked into the samples. The samples were submitted and analysis was requested using the vendor's QTOF platform and workflow that was specifically created for 'comprehensive drug screening'. Each vendor has developed a method and has optimized LC conditions, LC column, MS method, data acquisition and data analysis criteria for retention time, mass accuracy and area counts, according to limits of their instrumentation to support a broad spectrum drug screen. Therefore, it was not possible for each vendor to utilize similar LC and MS methods. While drug screening methods using QTOF have been previously published, there are very few studies comparing the performance of different instrument platforms as we have accomplished here. Results from this study will help to determine whether these three QTOF systems can provide MS-MS information for all spiked compounds under real-world conditions, thereby providing improved specificity over drug screening with TOF only.
Methods and materials

Sample preparation
Plasma samples P1-P3 were prepared from fresh frozen plasma from a single donor. Samples P1 and P2 were duplicate samples spiked with 66 drugs and metabolites listed in Table I . Sample P3 was not spiked. Plasma samples B1 -B6 and Q4 -Q9 were prepared from different lots of dialyzed plasma and spiked with 12 compounds of interest listed in Table II at 50 ng/mL. Urine samples U1 -U3 were prepared from drug-free urine. U1 and U2 had 37 compounds distributed between the two samples as listed in Table I . Sample U3 was not spiked. V1 -V6 and R17 -R22 were prepared from different lots drug-free urine spiked with the 12 compounds listed in Table II at 50 ng/mL. B1 -B6 and V1 -V6 
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Grand total in bold. þ, the sample was spiked at 50 ng/nL and compound was detected; 2, the sample was spiked at 50 ng/mL but the compound was not detected; Â, the compound was not included in the library used for detection.
were prepared in duplicate and sent to AB Sciex and Agilent; Q4 -Q9 and R17-R22 were prepared separately and sent to Waters. The concentrations of drugs in all samples were the same, but the combinations that were spiked between the B and Q and the V and R samples were slightly different. Detailed information is provided in Table II . P1 -P3 were prepared as previously reported (9) using a protein crash in acetonitrile, and sent as dry extracts in 1.5 mL max-recovery autosampler vials. U1 -U3 were sent as neat urine (1 mL each) in 1.5 mL max-recovery autosampler vials. The V and R (urine) samples were extracted by adding 10 mL of urine sample to a 25 mL tube and adding 2 mL saturated borate buffer. Next, 10 mL of 9 : 1 chloroform : isopropanol were added and the sample was rocked for 5 -10 min. The extracts were centrifuge for 5 -10 min at 2,000 -2,500 rpm, and the aqueous (top) layer was aspirated to waste. The organic layer was transferred to a silanized tube and 100 mL of 99 : 1 MeOH : HCl were added. The samples were dried under dessicated air at 408C and submitted to the three vendors as dried residue. The B and Q ( plasma) samples were extracted by adding 4 mL of plasma sample to a 10 mL sample tube and adding 1 mL of 0.3 M sodium phosphate, pH 6.5. The samples were mixed by shaking the tube gently, and 3-4 mL of ethyl acetate were added. The samples were gently vortex for 20 s, and centrifuged for 5 min at 2,000 rpm. The organic layer (top) was transferred to silanized screw cap tubes, and 50 mL of 99 : 1 MeOH : HCl was added, followed by 400 mL of 1 M KOH, then 2 -3 mL of ethyl acetate were added to the aqueous portion of the original plasma extract. The samples were vortexed gently for 20 s, then centrifuged for 5 min at 2,000 rpm. The organic layer was transferred to the same silanized screw cap tubes as the first ethyl acetate fraction. The samples were dried down under desiccated air at 408C and sent to each vendor for analysis as dried extracts.
LC-QTOF analysis
AB SCIEX TripleTOF 5600 system All plasma samples (P and B) and one set of urine samples (V) were re-dissolved in 75 mL methanol and centrifuged at 15,000g for 10 min, and the supernatant was diluted 10-fold in water (final diluent 10 : 90 methanol : water) for analysis in positive mode, and methanol : water (final composition 30 : 70 methanol : water) for negative mode analysis. Urine specimens U1-U3 were diluted 10-fold in 10 : 90 methanol : water for positive mode, and 30 : 70 methanol : water for negative mode. A 1290 Infinity LC and autosampler and an AB SCIEX TripleTOF 5600 system were used for data collection. A 50 Â 3 mm, 100 Å , 2.5 mm C 18 Kinetex column with a SecurityGuard cartridge (4 Â 3 mm 5 mm 60 Å C18) and holder (Phenomenex, Torrance, CA, USA) was used for LC separation. The LC gradient was 10 mM ammonium formate (A) and 50 : 50 acetonitrile : methanol (B), ramping from 2 to 100% B at 0.4 mL/min over 13 min. Total run time (with column re-equilibration) was 15.5 min. The column was maintained at 308C. The injection volume was 10 mL. Positive and negative mode electrospray ionization (ESI)-MS analysis on TripleTOF system were performed with TOF-MS full scan followed by information-dependent acquisition -MS-MS scan with 15 candidate ions. The MS scan time was 0.1 s (100 -650 m/z) and the each MS-MS scan was 50 ms (40 -650 m/z). The source parameters were as follows: source temperature 5008C, ion spray voltage 4,000 V, curtain gas 30, GS1 (nebulizing) 40 and GS2 (desolvating) 70. The instrument was re-calibrated every ten injections. Collection of fragment data was initiated by detection of a peak above a threshold of 100 cps with real-time dynamic background subtraction to reduce MS-MS scans for background ions thus improving chance of acquiring MS-MS scans on less abundant analytes. Collision energy spread was used for fragmentation in which the collision energy was continuously ramped from 20 to 50 eV in 0.05 s. Unknown identification and structure elucidation was performed using PeakView w and XIC Manager software (AB SCIEX). Compound identification was achieved by matching to a compound library that contained the compound formulas, retention times and fragmentation spectra. The initial criteria for a 'hit' was mass error less than +4 ppm, retention time difference within 0.5 min compared with established retention time, isotope ratio difference ,30%, and a purity score for MS-MS library matching. 'Tentative hits' with mass error as high as 6 ppm were reported. The purity score (%) is a measure of how well the MS-MS spectrum of the unknown compound matches the MS-MS library record of a known compound, and it takes into consideration (i) the presence/absence of all MS-MS spectral peaks and (ii) their relative abundances. The purity score will not return a high value if there are extraneous peaks present in the unknown spectrum, and therefore it provides highly accurate measure of similarity between the unknown MS-MS and the library record.
Agilent 6530 QTOF
The P samples were reconstituted in 100 mL of water. The B and V samples were diluted in 10 mL of water. U1-U3 were injected neat. An Agilent 1290 LC and Agilent's mid-range 6530 QTOF were used for data acquisition. An Agilent Zorbax Poroshell EC column (C 18 , 2.1 Â 100 mm, 2.7 mm) was used with a mobile phase of 0.01% formic acid/5 mM ammonium formate in water (A) and 0.01% formic acid in methanol (B) with a gradient ramping to 15% B over 1 min, continuing to 50% B at 6 min, and 90% B at 8 min, holding at 95% B for 1.5 min with a 1 min post time. Automatic column regeneration (9) was used. The column temperature was 558C. Total run time was 10.5 min. The injection volume was 10 mL for the B and V samples and 2 mL for the P and U samples. The QTOF was operated in positive and negative ESI mode as separate injections. Detector parameters were: drying gas heater 3258C, drying gas flow 9 L/min, nebulizer pressure 27 psi, capillary voltage 3,750 V, fragmenter voltage 175 V, sheath gas temperature 3808C and sheath gas flow 11 L/min. The nozzle voltage was 0 eV in positive mode and 21,500 eV in negative mode. Collection of fragment data was initiated by detection of a peak above 5,000 counts. Fragment data were collected at three separate collision energies: 10, 20 and 40 eV. Mass calibration correction was executed by introducing compounds of known mass (121.0509 and 922.0098 in positive mode, 119.0362 and 966.0073 in negative mode) via a second nebulizer during data acquisition and correcting each MS data scan. Data analysis was accomplished using MassHunter software (Agilent Technologies). Compounds were identified by matching Auto MS-MS obtained data to an accurate mass database containing retention time information and MS-MS libraries at three collision energies matching those of the acquisition method. Initial positive identification criteria were mass error +5 ppm, retention time +0.2 min and combined database and library score .75; however, tentative hits with mass errors as high as 12 ppm were reported. The combined database and library score is made up of several components. First, the database score is the combination of monoisotopic mass accuracy, the isotopic ion abundance match and the isotopic mass spacing of the measured spectrum compared with the theoretical database hit. Secondly, the MS-MS library score is a comparison of the fragmentation pattern of the measured analyte at three distinct and separate collision energies and compared with each respective fragmentation pattern held within the library. These results are combined with retention time (if present) to provide an overall match score.
Waters Xevo G2-S QToF
The P samples were reconstituted in 200 mL of 20% methanol in water for analysis. The U samples were diluted 1 : 10 with 20% methanol in water. The B and V samples were reconstituted in 100 mL 20% methanol in water and also run at a further 10-and 100-fold dilution. A Waters Acquity HSS C 18 , 2.1 Â 150 mm, 1.8 mm column and a mobile consisting of 5 mM ammonium formate, pH 3.0 (A, adjusted with formic acid) and acetonitrile with 0.1% formic acid (B) was used. A gradient with an initial hold at 13% B for 0.1 min, ramping to 50% B over 10 min, then to 95% B at 10.75 min, holding at 95% B for 1.5 min was used. The total run time with column equilibration was 15 min. The flow rate was 0.4 mL/min. The injection volume was 5 mL. Samples were analyzed in positive ESI mode only. The capillary voltage was 2 kV, the sampling cone voltage was 30 V. The source temperature was 1208C, desolvation temperature was 3008C. The cone gas flow was 0 L/h, and the desolvation gas flow was 600 L/h. LockSpray TM solution containing leucine/enkephalin was analyzed every 20 s for 0.2 s to adjust mass calibration of the instrument during analysis. Data were collected in MS E mode where the instrument alternated between low (6 eV for precursor ion collection) and high (10 -40 eV ramp for fragment ion collection) collision energies throughout the entire chromatographic run. Data were analyzed using Chromalynx TM application manager with MassLynx TM software (Waters Corporation). Positive matches require that the mass error of the precursor and fragment ion (if any) be less than +5 ppm and retention time be within 0.3 min of that defined in the library. Several tentative hits were also reported where either or both of the mass errors were between 5 and 20 ppm. In all cases, agents had to be within 0.3 min of the expected retention time.
Results
Compound detection could be affected by matrix effect, sample preparation and differences in the conditions, workflow and positivity criteria used by each vendor. Overall, all three platforms performed well detecting the majority of compounds spiked into the samples. This was a feasibility study to determine if LC-QTOF could successfully detect drugs and metabolites in urine and plasma. P1 and P2 were duplicate plasma samples. If a compound was detected in one or both samples, then it was considered a 'hit'. U1 and U2 had 37 spread out among the two spiked samples. A detailed discussion by sample type follows. All mass errors reported are absolute mass errors. Most reported compounds had mass errors of less than +5 ppm. The compounds with higher mass errors were similar among all three vendors and included amphetamine (all three vendors), methamphetamine (Agilent and Waters) and MDA (Waters) for the plasma samples; norfentanyl (Agilent), phentermine (Agilent and Waters) and temazepam (Waters) for the urine samples. Norfentanyl was not detected in the AB SCIEX or Waters urine samples, and temazepam was not detected in the AB SCIEX or Agilent urine samples. All other reported compounds had mass errors less than +5 ppm.
P1-P3
A summary of the results for samples P1-P3 is in Table III . P3 was negative dialyzed plasma and no compounds were detected by any of the vendors. Detection was 91-95% (66 possible compounds, 62 possible for G2-S results in positive mode only) for P1-P3. Average mass errors (absolute) ranged from 0.0 to 11.5 ppm. The TripleTOF 5600 system detected 60 of 66 compounds with an average purity score of 86 and an average mass error of 1.0 ppm. It did not detect six compounds: 6-monoacetylmorphine, chlordiazepoxide, m-OHbenzoylecgonine, n-desmethyltramadol, tapentadol and zopiclone. Four of 60 detected compounds had only TOF data, with no MS-MS data: MDMA, norbuprenorphine-6-glucuronide, norfentanyl and oxymorphone.
The 6530 QTOF also detected 60 of 66 compounds with an average target score of 88 and an average library score of 86. The average mass error was 2.3 ppm. Six compounds were not detected: chlordiazepoxide, cocaine, diazepam, o-desmethyltramadol, phentermine and temazepam. Eighteen of 60 detected compounds had only TOF data, because the library had no MS-MS spectra: 11-nor-9-carboxy-tetrahydrocannabinol, amobarbital, amphetamine, a-OH-alprazolam, a-OH-triazolam, butalbital, clonazepam, fentanyl, lorazepam, methylphenidate, m-OH-benzoylecgonine, morphine, norbuprenorphine glucuronide, norfentanyl, oxazepam, oxymorphone, secobarbital and zolpiclone.
The G2-S detected 59 of 62 possible compounds (62 possible because there was no negative mode data). The average mass error was 3.2 ppm. Average fragment mass error was 3.0 ppm. Three compounds were not detected: 11-nor-9-carboxytetrahydrocannabinol, m-OH-benzoylecgonine and ritalinic acid. Nine of 59 detected compounds had only TOF data, with no MS-MS data: 2-OH-ethylflurazepam, a-OH-triazolam, methylphenidate, morphine, norbuprenorphine, n-desmethyltramadol, o-desmethyltramadol, norfentanyl and tramadol.
U1-U3
The results summary for samples U1 -U3 are also in Table III . U3 was unspiked drug-free urine. No compounds of interest were detected in U3 by any of the vendors. Detection was 79 -85% (47 possible compounds) with average mass errors ranging from 0.0 to 9.8 ppm for all compounds and all platforms. The TripleTOF 5600 system detected 37 of 47 compounds with an average purity score of 83 and average mass error of 1.0 ppm. Four of 37 detected compounds had only TOF data, with no MS-MS data: amphetamine, buprenorphine, morphine and norbuprenorphine.
The 6530 detected 40 of 47 with an average target score of 94 and an average library score of 81. The average mass error was 1.8 ppm. Fifteen of 40 detected compounds had only TOF data, with no MS-MS library data: a-OH-alprazolam, clonazepam, fentanyl, hydromorphone, lorazepam, naloxone, n-desmethyltapentadol, norbuprenorphine-6-glucuronide, norfentanyl, norhydrocodone, normeperidine, noroxymorphone, oxazepam, tapentadol and tapentadol glucuronide. The G2-S detected 39 of 47 compounds with an average mass error of 4.0 ppm, and average fragment mass error was 4.0 ppm. Eleven of 39 detected compounds had only TOF data, with no MS-MS fragment data: 6-acetylmorphine, a-OH-alprazolam, a-OH-midazolam, buprenorphine, clonazepam, codeine, dihydrododeine, morphine, n-desmethyltramadol, norbuprenorphine and tramadol.
B1 -B6 and Q4 -Q9
These were both sets of six plasma samples spiked with the drugs listed in Table II . An empty cell means that drug was not spiked into that sample. The symbols indicate that it was spiked into that sample, and the type of symbol gives information on whether or not it was detected.
The Q samples were prepared first and sent to Waters. The B samples were prepared later in duplicate and sent to Agilent and AB SCIEX. Although the two sample sets were not identical, the same drug analytes were spiked in at the same concentrations for all (50 ng/mL). The combinations of drugs varied slightly in the B set and the Q set, but all drugs were represented, and both sets contained a sample with all 12 drugs. In the B set, all of the compounds were spiked into the various samples twice (n ¼ 24). The Q set had 9 of the compounds spiked into the 12 samples twice, but three of the compounds (amitriptylene, lidocaine and salicylate) were spiked in three times (n ¼ 27). Different lots of dialyzed plasma were used for the B and Q samples. Matrix effect was not evaluated. Refer to Table II for details. Both set of samples were extracted using the same extraction method. Although it is a limitation of the study, the authors feel that both set of samples are representative of the ability to detect the 12 compounds of interest and the results can be compared.
The TripleTOF 5600 system detected 21 of 24 spiked compounds. It did not detect gabapentin, ritalinic acid and salicylate in 1 of 2 spiked samples. The 6530 detected 19 of 24 spiked compounds; however, it did not detect gabapentin or salicylate (n ¼ 2), or ritalinic acid in 1 of 2 samples. The G2-S detected 19 of 27 spiked compounds. It did not detect acetaminophen in 1 of 3 samples, and meprobamate in 1 of 2 spiked samples. Gabapentin (n ¼ 3), salicylate and ritalinic acid (each n ¼ 2) were not included in the Waters compound library, and therefore would not be detected by the G2-S. This leaves 20 spiked results that Waters could have detected with their workflow.
V1-V6 and R17-R22
Detailed information on which drugs were spiked into which samples is listed in Table II . As in the B and Q plasma samples, there were slight variations in the combinations of drugs spiked into the samples, but the authors feel they were similar enough that the results can be compared. In the V set (sent to Agilent and AB Sciex), all of the compounds were spiked into the various samples twice (n ¼ 24) and one sample was spiked with all 12 compounds. The R set (sent to Waters) there was one specimen that was spiked with all 12 compounds. Nine of the compounds were spiked into the 12 samples twice, but three of the compounds (acetaminophen, carisoprodol and gabepentin) were spiked in three times among five of the specimens (making n ¼ 27 total spikes in 12 samples). Different lots of drug-free urine were used for the V and R samples. Matrix effect was not evaluated (refer to Table II for details).
The 5600 detected 20 of 24 spiked results, although it did not detect salicylate (n ¼ 2), and 1 meprobamate and 1 gabapentin of 2 spiked samples each. The 6530 detected 18 of 24 results, but it did not detect gabapentin, ritalinic acid or salicylate (n ¼ 2 each, 6 results total). The G2-S detected 18 of 27 spiked results. It did not detect acetaminophen in 1 of 3 spiked samples, and meprobamate in 1 of 2 spiked samples. Gabapentin, ritalinic acid and salicylate were not included in the Waters compound library, so these compounds would not be detected under these conditions. This leaves 20 possible positive results the G2-S should have detected in these samples.
Compounds reported but not spiked into samples P and U samples All three methods detected compounds that were not spiked into the samples. Caffeine, theobromine and theophylline were detected by all three vendors in the P or U samples with high scores and low mass errors, with MS-MS library matching. These results could not be verified, but these analytes are routinely detected in urine and plasma. These compounds are not included in the discussion below. Apart from these compounds, no other compounds not spiked into the samples were reported in the P and U samples by AB SCIEX. The Agilent 6530 detected six compounds that were not spiked into the P samples: ethotoin, gabapentin, lysergic acid, pregabalin, tapentadol-o-sulfate, zaleplone with an average target score of 88 and average mass error of 2.7 ppm. Only two compounds, gabapentin and lysergic acid, had fragment data, with an average library match score of 95. The 6530 also found 11 compounds that were not spiked into the U samples: ethotoin, fluvoxamine, lysergic acid, methocarbamol, nadolol, theobromine, vigabatrin, dimethadione, ethotoin, fluvoxamine, venlafaxine and nadolol with an average target score of 84 and average mass error of 4.3 ppm. All of these compounds had either a library match score of zero meaning the MS-MS data did not match the library spectra or there were no MS-MS library spectra for comparison. The library only contains spectra for the MþH adduct. Compound identification could have been from a 'TOF only' match of an adduct other than the MþH adduct. The Waters G2-S reported 13 compounds that were not spiked into the P samples: adrenaline/epinephrine, amitriptyline, carbidopa, desmethylclobazam, cortisone, eegonine methyl ester, lidocaine, hydroxyl metabolite of mephedrone, norneo sildenafil, prednisolone, desmethylpropoxyphene (propoxyphene degradation product, propoxyphene was spiked into the sample) and tryptophan, tyrosine. The average mass error was 4.2 ppm. Seven of the compounds had MS-MS fragment data with an average mass error of 4.3 ppm. The G2-S also reported 12 compounds not spiked into the U samples: adrenalone, allopurinol, amoxicillin, clobazam, glufosinate, lovastatin, N-methyl-1,3-benzodioxolylbutanamine (Eden), hydroxy metabolite of mephedrone, nadoxolol, paracetamol, tryptophan and tyrosine with an average mass error of 6.4 ppm. Fragment data were reported for five compounds with an average mass error of 7.0.
Compounds reported but not spiked into samples B, Q, V and R samples The 5600 found theobromine in all 6 B samples, and lidocaine in four of the samples that were not spiked with lidocaine. These results had low mass errors, good scores and a good MS-MS library match. The 6530 found guaifenesin (n ¼ 2), orphenadrine (n ¼ 2), levorphanol (n ¼ 1) and methylphenidate (n ¼ 1). MS-MS library data were only available for orphenadrine in the B samples. The G2-S QToF found buclizine (n ¼ 6), cortisol (n ¼ 1), lovastatin (n ¼ 2), OH-mephedrone (n ¼ 3), cerivastatin (n ¼ 1) and zolpidem (n ¼ 2) in the Q samples. None of G2-S results had matching fragment data.
The 5600 and the 6530 found diphenhydramine (n ¼ 3), theobromine (n ¼ 5), and acetaminophen, caffeine, nortriptyline, lidocaine and norfentanyl (each n ¼ 1) in the same V samples, but these compounds were not spiked into those samples. In addition, the 5600 found theophylline (n ¼ 6), caffeine (n ¼ 5), acetaminophen (n ¼ 2), norfentanyl, lidocaine, ecgonine methyl ester, methylphenidate, tramadol, levorphanol, dextromethorphan (each n ¼ 1), ketamine and norketamine (same sample) and methadone and EDDP (same sample) that were not spiked into the samples. All compounds had good match score and MS-MS library matches. The 6530 also found four compounds with MS-MS library match: levorphanol (n ¼ 2), orphenadrine and doxepin (each n ¼ 1). The 6530 also detected nine compounds without MS-MS library data, and one compound with an MS-MS match score of zero. The G2-S QToF detected diphenhydramine with matching MS-MS fragment data, and 17 compounds without an MS-MS fragment match in the R samples.
Discussion
Detection of these compounds that were not spiked into the samples could vary among the different platforms based on the compounds included the library, match criteria, differences in the algorithms used and the aggressiveness with which small peaks are considered to be significant when determining a 'hit'. As discussed, the detection of caffeine and its two metabolites in the samples was consistent on all three platforms, and all of these three identifications were supported by all possible components in the identification criteria. Among these components, MS-MS library matching provided the most comprehensive information of the compound's molecular structure and thus gave the highest confidence in determining a 'hit'. For the compounds that were not spiked but reported, it was observed in the majority of instances that no MS-MS match was found. The authors were encouraged that all three platforms reported a similar number of true positives, confirming the use of this technology as a viable alternative for a comprehensive drug screen. However, a case may be made for fully utilizing MS-MS fragmentation information to increase the identification accuracy of desired results. For a rugged and reliable method, MS-MS spectra would need to be added if it is missing from the library for all compounds of interest with any platform for accurate identification.
Since the collection of this data, Waters Corporation no longer recommends MassLynx w for accurate mass toxicology screening. UNIFI w is now the suggested software platform for data acquisition and processing. The UNIFI workflow was not used to process and report the results of this study; however, its capabilities were demonstrated at a later meeting. The UNIFI workflow would provide enhanced reporting and result tracking capabilities, easier to interpret reports, and the ability to securely review, approve and sign off on results and reports electronically when compared with Masslynx. At the time of evaluation, AB SCIEX had the best looking reports with a 'stop light' (green ¼ good, yellow ¼ fair and red ¼ poor) system for user-set criteria like retention time match, mass error and purity score. This made the report very easy to read and interpret. Agilent's report software was the easiest to modify by the end user because it is Microsoft Excel based.
All of the hardware performed well. Agilent and Waters have integrated acquisition software with the LC, sample management system and QTOF seamlessly incorporated into a complete system. AB SCIEX is not as seamless because it uses LC systems and autosamplers from various vendors. This can make set-up and acquisition more complicated but it does give more flexibility in designing an LC-QTOF system.
All of the systems had instrument tuning and mass calibration protocols that were easy to understand and run. Mass accuracy verification during a run was done differently by each vendor, but all seemed to perform well as demonstrated by the low mass errors observed for the results.
Summary
Overall, all three QTOF platforms performed well, with detection .90% for the P samples and better than 75% for the U samples.
Detection for the B and Q spiked plasma samples averaged 74 -88% of compounds detected. The V and R spiked urine samples averaged 74 -83% of compounds detected. There were some compounds that were difficult to detect among all three vendors, such as ampthetamine, methamphetamine and norfentanyl and phentermine, for example, and each of them reported a few 'tentative hits' with slightly higher mass errors. The authors believe that detection of these 'problem compounds' could be improved during additional method development and validation.
The compounds reported but not spiked into the samples generally had higher mass errors, lower scores, lower area counts and no MS-MS information. The good 'hits' from these compounds (e.g., caffeine, theobromine and dyphenhydramine) are routinely found in urine and plasma and were mostly found by more than one vendor. Considering samples were sent with minimal information, no prior knowledge of the compounds included and no direct instructions on how to analyze them other than a workflow for 'comprehensive drug screening' the results correlate remarkably well. When differences in hardware, software, chromatographic conditions, compound libraries, workflow, data analysis, positivity criteria and reporting are considered, the concordance of these results demonstrate the feasibility of the QTOF platform for drug screening, and that all three platforms could be considered for development and validation of a drug screening method. It is believed by these authors that the questionable results would be eliminated if a targeted method with optimized conditions were developed and validated. Collection of fragmentation data and comparison with a mass spectral library increases confidence in identification of drugs and metabolites, improves specificity and reduces the occurrences of false-positive results.
Conclusions
Despite differences in hardware, software and workflow, the three QTOF platforms evaluated demonstrated the capability for comprehensive drug screening. Additional method development and validation would be required for a rugged, reliable method.
